Aesthetics Sciences Completes Series-A $6 Million Funding.

Former Collagen Executives Lead Entry Into High Growth Markets

PALO ALTO, Calif. -- Aesthetic Sciences Corporation formed in 2004 to develop breakthrough products in the fields of aesthetic medicine and incontinence, announced the completion of its Series A financing with Domain Associates, LLC and New Leaf Venture Partners. Aesthetic Sciences Corporation (Aesthetic Sciences) received $3.2 million last week to complete the total of $6.0 million raised for the Series A financing.

Aesthetic Sciences Chairman and CEO Gary S. Petersmeyer commented, "We are very pleased to have this set of premier investors, along with our technology partner and one of the most experienced teams in our industry, as the foundation for our future growth and product innovations. In particular, with aging baby boomers, we expect facial aesthetic procedures to grow at a double digit annual rate for a number of years."

The Series A financing will continue the development of breakthrough technology for aesthetic procedures and the treatment of incontinence. Aesthetic Sciences has an exclusive license from Landec Corporation (Nasdaq:LNDC) for the worldwide use of Landec's patented materials technology in the fields of aesthetic medicine and incontinence.

Rebecca A. Stirn, Aesthetic Sciences President and CFO remarked, "This patented non-water technology will allow the development of a family of polymers designed to solve the long-standing issue of short persistence of many of the current products in the fields of aesthetic medicine and incontinence. This technology gives Aesthetic Sciences the potential to provide physicians and patients with a choice of products which will offer a range of persistence from over one year to more than five years."

Jesse Treu, Partner of Domain Associates, LLC and Director of Aesthetic Sciences said, "These extraordinary new materials have the potential to become the #1 choice in the dermal filler category. We believe Aesthetic Sciences can become a leader in this segment."

Kathy La Porte, Partner of New Leaf Ventures and Director of Aesthetic Sciences, added, "We look forward to working with the Aesthetic Sciences team, which brings tremendous background and a strong collective track record in aesthetic product development, business strategy and market positioning."

Gary Steele, Landec's President and CEO said, "We are pleased to see the progress of Aesthetic Sciences using Landec's polymer technology to create better solutions in these two areas of growing demand." Landec holds a minority interest in Aesthetic Sciences and will receive royalties on sales by Aesthetic Sciences in the designated fields of use.

About Aesthetic Sciences

Aesthetic Sciences Corporation, a Delaware corporate, was formed in October 2004 to develop and commercialize breakthrough products in the fields of aesthetic medicine and incontinence.

Gary S. Petersmeyer, Chairman and CEO of Aesthetic Sciences, is a co-founder and brings relevant and deep experience to Aesthetic Sciences based on his position as President and CEO of several medical and medical device companies, including Collagen Aesthetics Inc. and a division of CooperVision.

Rebecca A. Stirn, Aesthetic Sciences President and CFO, is a co-founder, and was VP of North American Sales and Marketing of Collagen Aesthetics Inc. Ms. Stirn has over 25 years of experience as VP of marketing and strategy with medical and medical device companies including Collagen, CEMAX, and Cooper Laboratories/CooperVision Inc.

Dr. Edward E. Schmitt, Chief Scientific Officer of Aesthetic Sciences, is a co-founder of Aesthetic Sciences and was formerly Chief Scientist of Landec Corporation, where he developed many of Landec's polymer applications for medical devices. Combining a background in polymer science with extensive experience in medical applications, Dr. Schmitt has created new technologies already defined in approximately 50 U. S. patents. He has extensive knowledge of polymer design and synthesis and was part of the team that invented and developed the World's first absorbable synthetic suture. Dr. Schmitt's experience includes leading research and development efforts at Coopervision Inc., Alza Corporation, and American Cyanamid.

For more information about Aesthetic Sciences please contact Gary S. Petersmeyer at 650-424-1810 or 650-823-8746.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ materially.